News
Obesity drugmaker Novo Nordisk said on Wednesday it would drop gender representation requirements for senior leadership ...
Novo Nordisk (NYSE: NVO), the Danish drugmaker that's been riding high ever since it began putting out Ozempic and Wegovy GLP-1 injectables for treatment of diabetes and weight loss, got another ...
Weight loss leader Novo Nordisk has had a poor performance at the stock markets year-to-date [YTD] even as the healthcare sector is among the least impacted ones. The key reason for this is ...
Conduct CT in India: CDSCO Panel tells Novo Nordisk India For new formulation of Semaglutide tablets
This came as Novo Nordisk India sought approval for Semaglutide tablets of 1.5 mg, 4 mg, and 9 mg of a new formulation based on the BE studies conducted in the USA and Canada. In light of earlier SEC ...
U.S.-listed shares of Novo Nordisk plunged 7% in intraday trading Thursday after rival Eli Lilly reported positive oral weight-loss drug news and BMO cut its rating for the Danish drug developer ...
While the momentum for Lilly is accelerating, that for Novo is slowing. In 2024, Lilly and Novo grew by 32% and 26%, respectively. This year, the gulf between their growth is expected to widen ...
Novo Nordisk has promoted Rishang Deoras to Global Director - Diabetes Commercial Unit. Deoras shared the news in a LinkedIn post, stating, "I'm excited to share that I've been promoted to Global ...
Novo Nordisk (NVO) has become aware of several hundred units of Ozempic injection 1 mg distributed outside the Novo Nordisk authorized supply chain in the U.S., the company announced.The Food and ...
Joining the consortium are Bristol Myers Squibb, COGNANO, Lambda, Novo Nordisk, Structure Therapeutics, Tamarind Bio, Unnatural Products, and Visterra, each bringing valuable expertise and a ...
Shares of weight-loss drugmakers Novo Nordisk A/S and Eli Lilly and Co. got a nice lift Monday, after a potential competitor decided to cancel development of its GLP-1 obesity drug. “We continue ...
April 14 (Reuters) - Danish drugmaker Novo Nordisk NOVOb.CO said on Monday several hundred counterfeit units of its diabetes drug Ozempic were being distributed outside its authorized supply chain ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results